BACKGROUND: Involvement of the proximal LAD is considered an indication for coronary artery bypass graft (CABG) surgery due to the high restenosis rates associated with this location after percutaneous coronary interventions (PCI). This seems to be different, however, when using sirolimus-eluting stents, a finding if proven to be true could have a major impact on clinical decision making regarding the optimal revascularization strategy for these patients. METHODS: We analyzed 2274 patients treated for proximal LAD stenoses using SES from the German Cypher Stent Registry. The incidence of TVR and other major clinical adverse events were determined and independent predictors of TVR were specified using a multiple logistic regression model. RESULTS: Event-free survival was achieved in 89.5% of patients. TVR was performed in 179 patients (7.9%) and the combined incidence of all cause death, myocardial infarction and TVR was 10.5% (231 patients). Independent predictors of TVR were multivessel disease (OR 1.74, 95% CI 1.16-2.62, p = 0.008), stent diameter < or = 2.75 mm (OR 1.61, 95% CI 1.10-2.40, p = 0.02) and the administration of GP IIb/ IIIa antagonists (OR 1.60, 95% CI 1.05-2.60, p = 0.03). TVR rate was as high as 11.2% for 2.5 mm SES and as low as 4.0% for 3.5 mm SES (p < 0.001 for trend test). CONCLUSION: TVR among patients treated with SES for proximal LAD stenoses is low and is related in part to operator dependent factors. Treatment with SES should be considered as an effective treatment for these patients.
BACKGROUND: Involvement of the proximal LAD is considered an indication for coronary artery bypass graft (CABG) surgery due to the high restenosis rates associated with this location after percutaneous coronary interventions (PCI). This seems to be different, however, when using sirolimus-eluting stents, a finding if proven to be true could have a major impact on clinical decision making regarding the optimal revascularization strategy for these patients. METHODS: We analyzed 2274 patients treated for proximal LAD stenoses using SES from the German Cypher Stent Registry. The incidence of TVR and other major clinical adverse events were determined and independent predictors of TVR were specified using a multiple logistic regression model. RESULTS: Event-free survival was achieved in 89.5% of patients. TVR was performed in 179 patients (7.9%) and the combined incidence of all cause death, myocardial infarction and TVR was 10.5% (231 patients). Independent predictors of TVR were multivessel disease (OR 1.74, 95% CI 1.16-2.62, p = 0.008), stent diameter < or = 2.75 mm (OR 1.61, 95% CI 1.10-2.40, p = 0.02) and the administration of GP IIb/ IIIa antagonists (OR 1.60, 95% CI 1.05-2.60, p = 0.03). TVR rate was as high as 11.2% for 2.5 mm SES and as low as 4.0% for 3.5 mm SES (p < 0.001 for trend test). CONCLUSION: TVR among patients treated with SES for proximal LAD stenoses is low and is related in part to operator dependent factors. Treatment with SES should be considered as an effective treatment for these patients.
Authors: Anno Diegeler; Holger Thiele; Volkmar Falk; Rainer Hambrecht; Niki Spyrantis; Peter Sick; Klaus W Diederich; Friedrich W Mohr; Gerhard Schuler Journal: N Engl J Med Date: 2002-08-22 Impact factor: 91.245
Authors: Sidney C Smith; Ted E Feldman; John W Hirshfeld; Alice K Jacobs; Morton J Kern; Spencer B King; Douglass A Morrison; William W O'neill; Hartzell V Schaff; Patrick L Whitlow; David O Williams; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: J Am Coll Cardiol Date: 2006-01-03 Impact factor: 24.094
Authors: S E Sheifer; M R Canos; K P Weinfurt; U K Arora; F O Mendelsohn; B J Gersh; N J Weissman Journal: Am Heart J Date: 2000-04 Impact factor: 4.749
Authors: Ahmed A Khattab; Andreas Otto; Ralph Toelg; Volker Geist; Lothar Klatt; Gert Richardt Journal: J Invasive Cardiol Date: 2005-11 Impact factor: 2.022
Authors: A A Khattab; C W Hamm; J Senges; R Toelg; V Geist; T Bonzel; M Kelm; B Levenson; C A Nienaber; G Sabin; S Schneider; U Tebbe; G Richardt Journal: Z Kardiol Date: 2005-03
Authors: R Zahn; C W Hamm; U Zeymer; S Schneider; C A Nienaber; G Richardt; M Kelm; B Levenson; T Bonzel; U Tebbe; W A Schöbel; G Sabin; J Senges Journal: Z Kardiol Date: 2004-04
Authors: Pedro A Lemos; Angela Hoye; Dick Goedhart; Chourmouzios A Arampatzis; Francesco Saia; Willem J van der Giessen; Eugene McFadden; Georgios Sianos; Pieter C Smits; Sjoerd H Hofma; Pim J de Feyter; Ron T van Domburg; Patrick W Serruys Journal: Circulation Date: 2004-03-01 Impact factor: 29.690
Authors: G S Mintz; J J Popma; A D Pichard; K M Kent; L F Salter; Y C Chuang; J Griffin; M B Leon Journal: J Am Coll Cardiol Date: 1996-06 Impact factor: 24.094
Authors: C Herdeg; K Göhring-Frischholz; U Helber; T Geisler; A May; K K Haase; M Gawaz Journal: Clin Res Cardiol Date: 2007-11-22 Impact factor: 5.460
Authors: Helge Möllmann; Albrecht Elsässer; Holger Nef; Steffen Schneider; Christoph A Nienaber; Gert Richardt; Michael Weber; Malte Kelm; Benny Levenson; Tassilo Bonzel; Ulrich Tebbe; Georg Sabin; Thomas Pfannebecker; Jochen Senges; Christian W Hamm Journal: Clin Res Cardiol Date: 2008-03-03 Impact factor: 5.460
Authors: T Schlosser; T Scheuermann; S Ulzheimer; O K Mohrs; M Kühling; P E Albrecht; T Voigtländer; J Barkhausen; A Schmermund Journal: Clin Res Cardiol Date: 2007-08-21 Impact factor: 5.460
Authors: Frank D Weber; Henrik Schneider; Marcus Wiemer; Thomas Pfannebecker; Ulrich Tebbe; Christian W Hamm; Jochen Senges; Steffen Schneider; Christoph A Nienaber Journal: Clin Res Cardiol Date: 2007-12-06 Impact factor: 5.460